VPAG is just the latest iteration of agreements struck between the UK government and industry. The minutes note that, whilst ...

Just as for previous schemes, metrics are being used to track VPAG, the UK’s voluntary scheme that covers branded medicines ...

Sales of Elevidys are quickly gaining ground on Sarepta's exon-skipping trio, which need to be dosed chronically. In the ...

Anglo-US contract development and manufacturing organisation (CDMO) Avid Bioservices has agreed a deal to be acquired by ...

Ayvakit has been recommended by NICE for ASM – an umbrella term that covers aggressive systemic mastocytosis, systemic mastocytosis with an associated haematological neoplasm (SM-AHN), and mast cell ...

The 6th RNAi-Based Therapeutics Summit is returning to Boston in January 2025 with fresh insights and perspectives.

Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial.

The Molecular Glue Drug Development Summit returns to Boston with fresh insights and opportunities! With powerhouse partnerships lighting up the industry—like Biogen & Neomorph, Inc.’s groundbreaking ...

Boston, US-based XRHealth is leading the deal, acquiring NeuroReality of the Netherlands for an undisclosed sum, combining their products and expertise in the use of XR and virtual reality software ...

Cassava then released the altered data in a press release and investor deck, which led the SEC to allege that the company and ...

Read Deep Dive: Patients & Partnerships in full pharmaphorum’s digital magazine Deep Dive provides objective, issue-driven ...

CD40 agonists have had mixed results in cancer to date, with Roche discontinuing its selicrelumab candidate after ...